156 related articles for article (PubMed ID: 38185471)
1. Comparison of diagnostic methods for detection of BRAFV600E mutation in ameloblastoma.
Anbinselvam A; Akinshipo AO; Adisa AO; Effiom OA; Zhu X; Adebiyi KE; Arotiba GT; Akintoye SO
J Oral Pathol Med; 2024 Jan; 53(1):79-87. PubMed ID: 38185471
[TBL] [Abstract][Full Text] [Related]
2. BRAFV600E mutation in the diagnosis of unicystic ameloblastoma.
Pereira NB; Pereira KM; Coura BP; Diniz MG; de Castro WH; Gomes CC; Gomez RS
J Oral Pathol Med; 2016 Nov; 45(10):780-785. PubMed ID: 27084044
[TBL] [Abstract][Full Text] [Related]
3. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours.
Diniz MG; Gomes CC; GuimarĂŁes BV; Castro WH; Lacerda JC; Cardoso SV; de Faria PR; Dias FL; Eisenberg AL; Loyola AM; Gomez RS
Tumour Biol; 2015 Jul; 36(7):5649-53. PubMed ID: 25854168
[TBL] [Abstract][Full Text] [Related]
4. Genetic Study of
Kokubun K; Yamamoto K; Akashi Y; Chujo T; Nakajima K; Matsuzaka K
Int J Surg Pathol; 2022 Jun; 30(4):378-384. PubMed ID: 34994576
[No Abstract] [Full Text] [Related]
5. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma.
Mendez LD; Wolsefer NS; Asa SL; Wasman J; Yoest JM; Stojanov IJ
Mod Pathol; 2022 Nov; 35(11):1570-1577. PubMed ID: 35676332
[TBL] [Abstract][Full Text] [Related]
6. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population.
Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S
Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063
[TBL] [Abstract][Full Text] [Related]
7. Absence of BRAFV600E immunohistochemical expression in sporadic odontogenic keratocyst, syndromic odontogenic keratocyst and orthokeratinized odontogenic cyst.
Jain KS; Bodhankar K; Desai RS; Bansal S; Shirsat P; Prasad P; Shah A
J Oral Pathol Med; 2020 Nov; 49(10):1061-1067. PubMed ID: 32589764
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting the accuracy of anti-BRAF V600E immunohistochemistry results in ameloblastomas.
Chang JYF; Lu PH; Tseng CH; Wang YP; Lee JJ; Chiang CP
J Oral Pathol Med; 2023 Apr; 52(4):342-350. PubMed ID: 36625499
[TBL] [Abstract][Full Text] [Related]
9. Association of MDM2 Overexpression in Ameloblastomas with
Tosios KI; Kalogirou EM; Koutlas IG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
[TBL] [Abstract][Full Text] [Related]
10. Discrepancy between immunohistochemistry and sequencing for BRAF V600E in odontogenic tumours: Comparative analysis of two VE1 antibodies.
Oh KY; Cho SD; Yoon HJ; Lee JI; Hong SD
J Oral Pathol Med; 2021 Jan; 50(1):85-91. PubMed ID: 32939809
[TBL] [Abstract][Full Text] [Related]
11. The importance of BRAF-V600E mutation to ameloblastoma metabolism.
Duarte-Andrade FF; Silva AMB; Vitório JG; Canuto GAB; Costa SFS; Diniz MG; Fernandes AP; de Toledo JS; André LC; Gomes CC; Gomez RS; Fonseca FP
J Oral Pathol Med; 2019 Apr; 48(4):307-314. PubMed ID: 30739334
[TBL] [Abstract][Full Text] [Related]
12. [Immunohistochemistry using clone VE1 is an economic, specific and sensitive method for detecting the presence of BRAFV600E mutations in melanoma].
Etienne M; Oca F; Prunier-Mirebeau D; Croué A; Martin L
Ann Dermatol Venereol; 2018 Mar; 145(3):159-165. PubMed ID: 29221650
[TBL] [Abstract][Full Text] [Related]
13. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.
Uguen A; Guéguen P; Legoupil D; Bouvier S; Costa S; Duigou S; Lemasson G; Ledé F; Sassolas B; Talagas M; Férec C; Le Maréchal C; De Braekeleer M; Marcorelles P
Hum Pathol; 2015 Nov; 46(11):1582-91. PubMed ID: 26297254
[TBL] [Abstract][Full Text] [Related]
14. Adenoid Ameloblastoma with BRAF p.V600E Mutation Revealing Ameloblastomatous Origin: A First Case Report.
Noda Y; Sawada S; Sakagami T; Kojima Y; Higasa K; Tsuta K
Head Neck Pathol; 2023 Sep; 17(3):788-792. PubMed ID: 37093491
[TBL] [Abstract][Full Text] [Related]
15. Molecular diagnostics in odontogenic tumors.
Buettner R; GĂĽltekin SE
Pathologie (Heidelb); 2022 Aug; 43(Suppl 1):81-85. PubMed ID: 36378285
[TBL] [Abstract][Full Text] [Related]
16. Does BRAF mutation status and related clinicopathological factors affect the recurrence rate of ameloblastoma? A systematic review, meta-analysis and metaregression.
Singh AK; Alagarsamy R; Chaulagain R; Singh A; Sapkota D; Thavaraj S; Singh RP
J Oral Pathol Med; 2023 Nov; 52(10):895-903. PubMed ID: 37872712
[TBL] [Abstract][Full Text] [Related]
17. BRAF p.V600E mutations are not unique to ameloblastoma and are shared by other odontogenic tumors with ameloblastic morphology.
Brunner P; Bihl M; Jundt G; Baumhoer D; Hoeller S
Oral Oncol; 2015 Oct; 51(10):e77-8. PubMed ID: 26306423
[No Abstract] [Full Text] [Related]
18. Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France).
Long E; Ilie M; Lassalle S; Butori C; Poissonnet G; Washetine K; Mouroux J; Lespinet V; Lacour JP; Taly V; Laurent-Puig P; Bahadoran P; Hofman V; Hofman P
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2436-43. PubMed ID: 26377147
[TBL] [Abstract][Full Text] [Related]
19. An immunohistochemical and genetic study of BRAF
Seki-Soda M; Sano T; Ito K; Yokoo S; Oyama T
Pathol Int; 2020 Apr; 70(4):224-230. PubMed ID: 31930640
[TBL] [Abstract][Full Text] [Related]
20. Genetic heterogeneity and enrichment of variants in DNA-repair genes in ameloblastoma.
Awotoye W; Whitt JC; Yoo B; Farooqi MS; Farrow EG; Allareddy V; Amendt BA; Rengasamy Venugopalan S
J Oral Pathol Med; 2023 Mar; 52(3):263-270. PubMed ID: 36715450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
